{"id":1035223,"date":"2020-01-29T16:46:28","date_gmt":"2020-01-29T21:46:28","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/adverum-biotechnologies-to-present-additional-data-from-the-optic-phase-1-trial-with-advm-022-intravitreal-gene-therapy-in-wet-amd-at-the\/"},"modified":"2024-08-17T15:44:30","modified_gmt":"2024-08-17T19:44:30","slug":"adverum-biotechnologies-to-present-additional-data-from-the-optic-phase-1-trial-with-advm-022-intravitreal-gene-therapy-in-wet-amd-at-the","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/gene-medicine\/adverum-biotechnologies-to-present-additional-data-from-the-optic-phase-1-trial-with-advm-022-intravitreal-gene-therapy-in-wet-amd-at-the.php","title":{"rendered":"Adverum Biotechnologies to Present Additional Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the&#8230;"},"content":{"rendered":"<p><p>REDWOOD CITY, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of 24-week data from the second cohort of patients (n=6; 2 x 1011 vg\/eye) as well as an update from the first cohort of patients (n=6; 6 x 1011 vg\/eye) in the OPTIC Phase1 clinical trial of ADVM-022 intravitreal gene therapy in wet AMD at the Angiogenesis, Exudation, and Degeneration 2020 Meeting.<\/p>\n<p>Adverum plans to issue a press release relating to the presentation and post the presentation on Adverums website at <a href=\"http:\/\/www.adverum.com\" rel=\"nofollow\">http:\/\/www.adverum.com<\/a> in the Investors section under the Events and Presentations page at the beginning of the data presentation at Angiogenesis.<\/p>\n<p>KOL Event Details:In addition, Adverum will host an event with expert retinal specialists to discuss the OPTIC data presented at Angiogenesis and the potential opportunity for ADVM-022. The discussion will be held on Sunday, February 9, 2020 beginning at 10:00 am EST. The event will be webcast live from Adverums website at <a href=\"http:\/\/www.adverum.com\" rel=\"nofollow\">http:\/\/www.adverum.com<\/a> in the Investors section under the Events and Presentations page. A replay of the webcast will be archived and available for replay following the event.<\/p>\n<p>About Adverum BiotechnologiesAdverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. For more information, please visit <a href=\"http:\/\/www.adverum.com\" rel=\"nofollow\">http:\/\/www.adverum.com<\/a>.<\/p>\n<\/p>\n<p><!-- Auto Generated --><\/p>\n<p>More:<br \/>\n<a target=\"_blank\" href=\"https:\/\/www.biospace.com\/article\/releases\/adverum-biotechnologies-to-present-additional-data-from-the-optic-phase-1-trial-with-advm-022-intravitreal-gene-therapy-in-wet-amd-at-the-angiogenesis-exudation-and-degeneration-2020-meeting\/\" title=\"Adverum Biotechnologies to Present Additional Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the...\" rel=\"noopener noreferrer\">Adverum Biotechnologies to Present Additional Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> REDWOOD CITY, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/gene-medicine\/adverum-biotechnologies-to-present-additional-data-from-the-optic-phase-1-trial-with-advm-022-intravitreal-gene-therapy-in-wet-amd-at-the.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246858],"tags":[],"class_list":["post-1035223","post","type-post","status-publish","format-standard","hentry","category-gene-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1035223"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1035223"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1035223\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1035223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1035223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1035223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}